Joseph Frattaroli
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Joseph Frattaroli
Earlier roles on record: CFO at Inhibikase Therapeutics, Inc. (IKT) until March 31, 2024. Inhibikase Therapeutics, Inc. reported in an 8-K filed January 16, 2024 that Joseph Frattaroli retired as Chief Financial Officer, effective March 31, 2024. The proxy statement of Inhibikase Therapeutics, Inc. reports total compensation of $370,383 for Joseph Frattaroli in fiscal 2024, including a base salary of $354,868. Disclosed compensation is on record for 6 fiscal years. Joseph Frattaroli has spoken on 6 earnings calls across 1 company, most recently for Inhibikase Therapeutics, Inc. on September 30, 2023.
“On January 16, 2024, Joseph Frattaroli provided notice to the Board of Directors (the "Board") of Inhibikase Therapeutics, Inc. (the "Company") of his intention to retire as Chief Financial Officer of the Company, effective at the end of the first quarter of 2024 or March 31, 2024.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Start not stated–2024-03-31
Company network
Recorded roles and call appearances connecting this person to public companies.
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Inhibikase Therapeutics, Inc. (IKT) | Former Chief Financial Officer | $354,868 | $370,383 |
| 2023 | Inhibikase Therapeutics, Inc. (IKT) | Former Chief Financial Officer | $408,333 | $579,964 |
| 2022 | Inhibikase Therapeutics, Inc. (IKT) | C.P.A. Former Chief Financial Officer | $395,833 | $574,765 |
| 2021 | Inhibikase Therapeutics, Inc. (IKT) | C.P.A. Chief Financial Officer | $375,000 | $487,500 |
| 2020 | Inhibikase Therapeutics, Inc. (IKT) | C.P.A. Chief Financial Officer | $300,000 | $1,642,220 |
| 2019 | Inhibikase Therapeutics, Inc. (IKT) | C.P.A. Chief Financial Officer | $300,000 | $300,000 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.